Conclusion Based on the current evidence , BTX-A may be an effective and safe option for the treatment of neuralgia .
Aim This meta- analysis was performed to evaluate the efficacy and safety of botulinum toxin-A ( BTX-A ) for the treatment of neuralgia .
Botulinum toxin injection for management of thoracic outlet syndrome: A double-blind, randomized, controlled trial
Summary Botulinum toxin injections to the scalene muscles did not reduce pain in subjects with thoracic outlet syndrome in this double‐blind , r and omized , controlled trial . ABSTRACT We studied the effect of botulinum toxin type A ( BTX‐A ) injections to the scalene muscles on pain in subjects with thoracic outlet syndrome ( TOS ) in this double‐blind , r and omized , parallel group trial with follow‐up at 6 weeks , 3 months , and 6 months . Thirty‐eight patients referred to physiatrists for management of TOS with BTX‐A injection were included . One subject was lost to follow‐up and all other subjects completed the trial . A 75‐unit dose of BTX‐A reconstituted with 0.75 cc of normal saline was injected to the anterior scalene ( 37.5 units ) and middle scalene ( 37.5 units ) muscles using electromyographic guidance . The primary outcome measure was pain as measured on a horizontal visual analog scale ( VAS ) 6 weeks‐post‐injection . Secondary outcomes were paresthesias measured on a VAS and function measured with the Disabilities of the Arm , Shoulder and H and ( DASH ) and Short‐form 36 ( SF‐36 ) question naires . For the primary outcome measure of VAS scores for pain at 6 weeks , the difference in the means adjusted for baseline VAS scores between placebo and BTX‐A was 5.03 mm in favor of BTX‐A ( 95 % confidence interval −15.7 to 5.7 , P = .36 ) . Changes in secondary outcome measures were also not statistically significant . We conclude that BTX‐A injections to the scalene muscles did not result in clinical ly or statistically significant improvements in pain , paresthesias , or function in this population of subjects with TOS
Conclusion Based on the current evidence , BTX-A may be an effective and safe option for the treatment of neuralgia .
Aim This meta- analysis was performed to evaluate the efficacy and safety of botulinum toxin-A ( BTX-A ) for the treatment of neuralgia .